Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arbidol hydrochloride tablets for COVID-19 pneumonia
ChiCTR2000029621Phase 4Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of umifenovir in coronavirus disease 2019 (COVID-19) and pneumonia (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Virus negative conversion rate in the first week. Started Jan 2020; status: recruiting.
02
Drugs
umifenovir
03
Conditions
coronavirus disease 2019 (COVID-19)pneumonia
Beyond the preview
Go deeper on ChiCTR2000029621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029621.